Evolution of the Average Target: Summit Therapeutics Inc.

Evolution of the Target Price: Summit Therapeutics Inc.

Changes in Analyst Recommendations: Summit Therapeutics Inc.

6b7413ad.Z6D9z4Aj8ZpswOFhtP_raN8OibeDEBtDNgxeeL67twk.D-uz4u0RtN1YidAzg76tDu9Hv9rEInF0D31vC-709W4E7rGox0aFwAOR1Q~c91aebd13ce839ba3ceca55b4c14be5a
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
07-24 Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept MT
06-22 Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials… Zonebourse
05-27 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
05-22 Summit Therapeutics Shares Fall After HC Wainwright Downgrade MT
05-22 Bernstein Initiates Summit Therapeutics at Underperform MT
05-22 HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
12-17 Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16 MT
25-10-21 Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley… Zonebourse
25-10-20 Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results CI
25-09-17 Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target MT
25-09-04 Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target MT
25-08-19 Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target MT
25-08-13 Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says MT
25-07-01 UBS Initiates Summit Therapeutics at Buy With $30 Price Target MT
25-06-11 Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target MT
25-05-08 TD Cowen Initiates Summit Therapeutics at Buy MT
25-04-25 Top Midday Decliners MT
25-03-26 Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23 MT
25-03-21 Cantor Fitzgerald Initiates Summit Therapeutics at Overweight MT
25-03-12 Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
Average
Weighted average by Cap.


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.66GBP
Average target price
21.56GBP
Spread / Average Target
+57.77%
High Price Target
30.81GBP
Spread / Highest target
+125.47%
Low Price Target
8.126GBP
Spread / Lowest Target
-40.53%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. SMMT Stock
  4. Consensus Summit Therapeutics Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!